MELISSA GRAHAM: Open Payments
NPI 1164205415 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$942 in 52 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,241 · 2025 $942
Food & beverage: $942
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $178 |
| Neurocrine BioSciences, Inc. | 9 | $155 |
| Lundbeck LLC | 5 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Janssen Pharmaceuticals, Inc | 3 | $69 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| ACADIA Pharmaceuticals Inc | 2 | $51 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Tempus AI, Inc | 1 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
Products named: REXULTI, INGREZZA, TRINTELLIX, FANAPT, NUPLAZID, SPRAVATO, COBENFY, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
